Evaluation of a 3D Functional Metabolic Imaging and Risk Assessment System for Classifying Women at High Risk of Breast Cancer
| Status: | Recruiting |
|---|---|
| Conditions: | Breast Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 30 - 70 |
| Updated: | 4/17/2018 |
| Start Date: | May 2016 |
| End Date: | November 2018 |
| Contact: | David Izhaky |
| Email: | David@realimaging.com |
| Phone: | +972-3-972-0602 |
Evaluation of a Three Dimensional Functional Metabolic Imaging and Risk Assessment System for Classifying Women at High Risk of Breast Cancer
The objective of the study is to estimate the diagnostic accuracy of cancer detection when
MIRA technology is combined with mammography, by evaluating the area under the ROC curve
(AUC) of mammography vs. mammography plus MIRA. This evaluation will be done in a Reader
Study on a subset of women with histology confirmed cancer and healthy women with dense
breast.
MIRA technology is combined with mammography, by evaluating the area under the ROC curve
(AUC) of mammography vs. mammography plus MIRA. This evaluation will be done in a Reader
Study on a subset of women with histology confirmed cancer and healthy women with dense
breast.
Inclusion Criteria:
A. Subjects who are asymptomatic and scheduled to undergo routine screening mammography
OR
B. Subjects scheduled for image guided needle biopsy as a result of findings obtained
during standard of care imaging modalities
AND
C. Subjects has a prior mammogram and have been diagnosed with extremely or heterogeneously
dense breast tissue (Density C or D)
Exclusion Criteria:
1. Male by birth.
2. Individual is less than 30 and greater than 70 years old.
3. Contraindication to bilateral mammography or MRI
4. Subjects who are unable to read, understand and execute the informed consent
procedure.
5. Subjects who have had mammography ultrasound or MRI examination performed on the day
of the study prior to MIRA scan.
6. Subjects who have significant existing breast trauma.
7. Subjects who have undergone lumpectomy/mastectomy.
8. Subjects who have undergone breast reduction or breast augmentation.
9. Subjects who have undergone any other type of breast surgery, excluding surgical
biopsy.
10. Subjects who have large breast scar / Breast deformation
11. Subjects who have undergone a breast needle biopsy or a surgical biopsy within the 6
month period prior to their intended enrollment into the study.
12. Subjects who have a temperature > 100° F (37.8C) degrees on the day of the MIRA
imaging
13. Subjects who are pregnant or lactating
14. Subjects with known Raynaud's Disease
15. Subjects that are claustrophobic or have physical limitations that do allow them to
sit in the system chair for the required imaging session.
16. Subjects with implanted pacemaker/defibrillator, implanted venous access device
(portacath) or other implanted devices
17. Subject with kidney failure
18. Subject with known allergy to gadolinium
19. Subject with a history of multiple contrast MRI scans (more than 4 MRI scans over the
past two year)
20. Inmates (45 CFR 46.306) or mentally disabled individuals
21. Subjects with a BI-RADS category 6 (e.g. for which mammogram was performed for the
purpose of planning cancer therapy)
22. Subjects currently participating in another investigational clinical study
23. Subjects who participated in the Calibration Phase will not be able to participate in
the Testing Phase
We found this trial at
1
site
Laguna Hills, California 92653
Principal Investigator: Gary Levine, MD
Phone: 949-452-7356
Click here to add this to my saved trials
